Introduction
Sulfonamides are one of the oldest group of synthetic drugs. Investigations of the antibiotic properties of Prontosil (streptocide) made it possible to find of its activity source: metabolite Sulfanilamide ( Fig. 1) which formed in organism through hydrolysis. 1 This discovery initiated the era of drugs' directed synthesis and the study of the structure-activity relationship. Later it was shown that the list of bioactive sulfonamides is not limited to derivatives of benzenesulfonic acid, and among these substances not only effective antibiotics can be found. Even the simple functionalization of arylsulfonamides helped to create drugs that are effective in treating a wide range of diseases. A connection of the sulfonamide fragment to a variety of heterocyclic systems, either directly or through a linker, has significantly increased the number of sulfonamides suitable for use in different fields of medicine ( Fig. 1) .
Fig. 1. Sulfonamide drugs
It is not surprising that researchers widely use sulfonamides also to solve one of the most burning problems of our time, namely the treatment of cancer. Now there are a number of sulfonamide drugs that can stop the growth of different types of malignant cells; and some of them can combine anticancer with other kinds of bioactivity, such as Celecoxib, an anti-inflammatory agent that caused an apoptosis and a decrease in angiogenesis of tumors and metastases (Fig. 2) . However, the situation in this branch is still not flawless, so searching for new substances with anticancer activity will be vital task for a long time.
Fig. 2. Sulfonamide drugs with anticancer activity
The efforts of our department in collaboration with National Cancer Institute (NCI) are aimed at finding new anticancer drugs among N-heterocycles, including structures with sulfonamide residues. It was found by us earlier that some oxazole 2, 3 and thiazole 4 sulfonamide derivatives have the necessary level of anticancer activity. In the course of these investigations, we have paid attention to small sulfonamide type molecules with functionalized heterocyclic fragment. It should be noted that similar potential anti-cancer drugs have being actively studied now, e.g. the carbonic anhydrase IX (CAIX) inhibitor DTP348 (Fig. 2) is among them. 5 This paper informs about the detection of high anticancer activity of the new heterocyclic derivatives with the sulfonamide fragment -(Z)-N-(5-(dichloromethylene)-2-oxoimidazolidin-4-ylidene)-N'-alkyl-or N',N'-dialkylsulfonamides. These compounds were tested for their in vitro antitumor activity against a panel of 60 cancer cell lines at the National Cancer Institute, USA, within the framework of Developmental Therapeutic Program (http://dtp.cancer.gov).
Results and Discussion

Synthesis and Structure Determination
It can be seen that the valid sulfonamide drugs contain in molecule various active functional groups or labile heterocycles ( Fig. 1, 2) ; so why the preparation of such derivatives using the sulfochlorination stage involves some difficulties. Therefore, to synthesize new imidazolinone containing sulfonamides, we chose a different approach (Scheme 1), and formed this heterocycle system using a reagent already containing the sulfochloride group -chlorosulfonyl isocyanate. Another component of the reaction was 2-amino-3,3-dichloroacrylonitrile 6 (ADAN), that previously was well recognized as a convenient precursor for the synthesis of functionalized heterocycles, 7, 8 including reaction with tosyl isocyanate. 9 In the first stage, compound 1, being an extremely strong electrophile, acylates the amino group of ADAN 2, although its low nucleophilicity. It caused heterocyclization involving a cyano group; and recyclization of the intermediate 4 gives the target sulfochloride 5. The compound 5 easily reacted with aliphatic primary or secondary amines (excess), and sulfonamides 6a-e were obtained; chemical structures, yeald and melting points are given at According to X-ray analysis of compound 6d, C=N-bond is in Zconfiguration with the N3-C5-N2-S1 torsion angle of -8.4(3)º (Fig. 3) ; that was predictable, because in such a structure steric hindrance is less. 
Biological Evaluation
Primary Single High Dose (10 −5 M) against Full NCI 60 Cells Panel in Vitro Assay
Initial single dose (10 -5 M) testing of primary choosing sulfonamides 6b (NSC 802751), 6c (NSC 802752), and 6e (NSC 795241) against the 60 cell lines of NCI immediately made it possible to select the most promising objects -piperidine derivative 6c and isonipecotate 6e. On Figs. 4 one dose mean graphs of the percent growth of the treated cells when compared to the untreated control cells for compounds 6b,c,e is shown.
As we can see the most active compounds 6c,e mainly have high selectivity to the cancer cell lines. Benzylamide 6b didn't exhibit such a pronounced cytotoxicity, but some data is quite interest to use them subsequently. In despite of the summarily weak level of compound 6b bioactivity, its exterminating of two lines of breast cancer (T-47D and MDA-MB-468) was unexpectedly notable (Figs. 4) . Also it was remarkable the moderate but unequivocal predisposition of the amide 6b to cause the death of almost all investigated leukemia cells lines. The presented facts allow expecting for the high selectivity of this substance and its analogues to various biological targets.
Five Doses Full NCI 60 Cell Panel Assay
The next step was to find the extrapolating parameters GI50, TGI, and LC50 for substances 6c,e (definition and method of calculation see below in experimental section). Control samples of 60 cancer cell lines were compared with the ones that treated by sulfonamides 6c,e in five different concentration (10 -8 , 10 -7 , 10 -6
, 10 -5 and 10 -4 M).
By measuring of optical densities of cell medium percent growth was defined (see Table 2 ,3). These data are completely visualized on Figures 5 and the most significant information is exposed in Table 4 . High cytotoxical ability of substances 6c,e is confirmed by the LC50 value, which in some cases was micromolar; e.g. for sulfonamide 6c in action to Melanoma LOX IMVI and breast cancer MDA-MB-231/ATCC and for sulfonamide 6e to MDA-MB-231/ATCC.
Conclusions
Thus, a convenient method for the synthesis of new (Z)-N-(5-(dichloromethylene)-2-oxoimidazolidin-4-ylidene)-N'-substituted sulfonamides with variation of amino compounds has been developed and high anticancer activity of two of the six derivatives has been set. 
Disclaimer
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Experimental
General Methods
All reagents and solvents were purchased from Aldrich and used as received.
1 H (400 MHz) and 13 C (100 MHz) NMR spectra were recorded at Varian Unityplus 400 spectrometer in DMSO-d6 solution with TMS as an internal standard. IR spectra were recorded on a Vertex 70 spectrometer from KBr pellets. The melting points were estimated on a Fisher-Johns instrument.
The chromatomass spectra were recorded on an Agilent 1100 Series high performance liquid chromatograph equipped with a diode matrix with an Agilent LC/MS mass selective detector allowing a fast switching the positive/negative ionization modes. The reaction progress was monitored by the TLC method on Silica gel 60 F254 Merck.
Synthetic Procedures and Spectral Data
(Z)-(5-(Dichloromethylene)-2-oxoimidazolidin-4-ylidene)-sulfamoyl chloride (5).
Chlorosulphonyl isocyanate 1 (20.28 ml, 0.233 mol) was added dropwise with stirring to a solution of ADAN 2 (31.0 g, 0.233 mol) in absolute Et2O (300 ml), and the mixture was stirred at 30-35 °C for 14 h. The resulting precipitate was collected by filtration and washed with Et2O. Yield 85-90 %. Mp 120-125 °C (decomp. 
Sulfonamides 6a-e Synthesis.
To a solution of 6 eq (21.6 mmol) of corresponding amine in 50 ml of THF at 0-5 °C sulfamoyl chloride 5 (1 g, 3.6 mmol) was added with stirred in portions about 0.1 g. Reaction mixture was stirred at 20-25 °C for 6 h, then the solvent was evaporated in vacuo. To residue 10 ml of water was added and the mixture was acidified by diluted HCl. The precipitate that formed was filtered off, dried and recrystallized from ethanol. 
N-[(4Z)-5-(Dichloromethylidene)-2-oxoimidazolidin-4-ylidene]-N-methylsulfuric diamide (6a
N-[(4Z)-5-(Dichloromethylidene)-2-oxoimidazolidin-4-ylidene]morpholine-4-sulfonamide (6d
Ethyl
1-{[(4Z)-5-(Dichloromethylidene)-2-oxoimidazolidin-4-ylidene]sulfamoyl}piperidine-4-carboxylate (6e).
1 H NMR (400 MHz, DMSO-d6), δ, ppm (J, 
1-{[(4Z)-5-(Dichloromethylidene)-2-oxoimidazolidin-4-ylidene]sulfamoyl}piperidine-4-carboxylic acid (6f).
Ester 6e (1 g, 2.5 mol) in KOH water solution (0.28 g, 5 mmol KOH in 5 ml of water) was heated with stirring up to boiling and solving. After cooling reaction mixture was acidified by diluted hydrochloric acid, and precipitate was filtered off, dried and recrystallized from ethanol. 1 
X-Ray Analysis
The colourless crystals of sulfonamide 6d (C8H10O4N4Cl2S) are monoclinic. At 293 K a = 5.8274(2), b = 18.4851(5), c = 12.4109(3) Å, β = 102.555(3)°, V = 1304.92(7) Ǻ 3 , Mr = 329.16, Z = 4, space group P21/c, dcalc = 1.675 g/сm 3 , (MoK  ) = 0.673 mm -1 , F(000) = 672. Intensities of 10648 reflections (3000 independent, Rint=0.033) were measured on the «Xcalibur-3» diffractometer (graphite monochromated MoKα radiation, CCD detector, ω-scaning, 2Θmax = 55). The structure was solved by direct method using SHELXTL package 10 . Positions of the hydrogen atoms were located from electron density difference maps and refined using "riding" model with Uiso = 1.2Ueq of the carrier atom. Fullmatrix least-squares refinement against F 2 in anisotropic approximation for non-hydrogen atoms using 3000 reflections was converged to wR2 = 0.085 (R1 = 0.035 for 2504 reflections with F>4σ(F), S = 1.024). The final atomic coordinates, and crystallographic data for molecule 6d have been deposited to the Cambridge Crystallographic Data Centre, 12 Union Road, CB2 1EZ, UK (fax: +44-1223-336033; e-mail: deposit@ccdc.cam.ac.uk) and are available on request quoting the deposition numbers CCDC 1894776). Table 1 ), respectively Primary in vitro one dose anticancer screening was initiated, in which the full NCI 60 panel lines were inoculated onto a series of standard 96-well microtiter plates on day 0 at 5000-40,00 cells/well in RPMI 1640 medium containing 5 % fetal bovine serum and 2 mM L-glutamine, and then preincubated in absence of drug at 37 °C, and 5 % CO2 for 24 h. Test compounds were then added at one concentration of 10 −5 M in all 60 cell lines, and incubated for a further 48 h at the same incubation conditions. Following this, the media were removed, the cells were fixed in situ, washed, and dried. The sulforhodamine B assay is used for cell density determination, based on the measurement of cellular protein content. After an incubation period, cell monolayers are fixed with 10 % (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1 % (vol/vol) acetic acid. The bound stain was resolubilized in 10 mM Tris base solution and measured spectrophotometrically on automated microplate readers for OD determination at 510 nm.
In Vitro Anticancer
Five Doses Full NCI 60 Cell Panel Assay.
All the 60 cell lines, representing nine cancer subpanels, were incubated at five different concentrations (0.01, 0.1, 1, 10 and 10 µM) of the tested compounds. The outcomes were used to create log10 concentration versus percentage growth inhibition curves and three response parameters (GI50, total growth inhibition (TGI) and LC50) were calculated for each cell line. The GI50 value (growth inhibitory activity) corresponds to the concentration of the compound causing 50 % decrease in net cell growth. The TGI value (cytostatic activity) is the concentration of the compound resulting in total growth inhibition. The LC50 value (cytotoxic activity) is the concentration of the compound causing net 50 % loss of initial cells at the end of the incubation period of 48 h. The three dose response parameters GI50, TGI and LC50 were calculated for each experimental compound. Data calculations were made according to the method described by the NCI Development Therapeutics Program (https://dtp.cancer.gov/discovery_development/nci-60/default.htm).
The % growth curve is calculated as: [(T -T0) / (C -T0)] × 100, where T0 is the cell count at day 0, C is the vehicle control (without drug) cell count (the absorbance of the SRB of the control growth), T is the cell count at the test concentration at day 3.
The GI50 and TGI value are determined as the drug concentration that results in a 50 % and 0 % growth at 48 hr drug exposure. Growth inhibition of 50 % (GI50) is calculated from: [(T -T0) / (C -T0)] × 100 = 50.
The TGI is the concentration of test drug where: 100 × (T -T0) / (C -T0) = 0. Thus, the TGI signifies a cytostatic effect.
The LC50, which signifies a cytotoxic effect, is calculated as: [(T -T0) / T0] × 100 = -50, when T < T0.
